Posted by Michael Wonder on 03 May 2020
Agenda for the July 2020 PBAC meeting (revised)
1 May 2020 - Published on Wednesday and revised (with no notification) by Friday.
The revised agenda includes a minor submission from Emerge Health for adrenaline (not epinephrine) for use by patients with an acute allergic reaction including anaphylaxis.
A few other (minor) insights:
- The new guselkumab (Tremfya) pre-filled pens have a concentration of 100 mg/mL
- The ordering of the components in combination products is a mess; is it indacaterol and glycopyrronium and mometasone or mometasone and indacaterol and glycopyrronium? The PBAC is clearly confused.
